Prasugrel provides faster, stronger, and more consistent platelet inhibition compared to clopidogrel. However, it also increases the risk of bleeding, especially in high-risk groups such as those over age 75, weighing less than 60kg, or with a history of stroke or transient ischemic attack. The TRITON-TIMI 38 trial found that prasugrel reduced cardiovascular events compared to clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, but increased major bleeding risks. Subgroup analyses identified populations that may derive particular benefit or face specific bleeding risks with prasugrel.